Shares of Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) have received an average rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $7.20.
Several brokerages recently issued reports on ELEV. JMP Securities restated a “market outperform” rating and set a $7.00 price objective on shares of Elevation Oncology in a research note on Thursday, December 19th. William Blair began coverage on shares of Elevation Oncology in a research report on Friday. They issued an “outperform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a report on Friday, December 13th. Finally, Stephens reiterated an “overweight” rating and set a $5.00 price objective on shares of Elevation Oncology in a research note on Friday, December 6th.
Check Out Our Latest Research Report on ELEV
Elevation Oncology Price Performance
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.02). Equities analysts expect that Elevation Oncology will post -0.85 EPS for the current fiscal year.
Institutional Trading of Elevation Oncology
A number of large investors have recently modified their holdings of the company. American Century Companies Inc. grew its position in Elevation Oncology by 55.7% in the 2nd quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock worth $133,000 after purchasing an additional 17,602 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of Elevation Oncology during the second quarter worth approximately $103,000. JPMorgan Chase & Co. grew its holdings in Elevation Oncology by 175.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 61,334 shares of the company’s stock worth $37,000 after buying an additional 39,101 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Elevation Oncology in the 3rd quarter valued at approximately $28,000. Finally, Barclays PLC increased its position in Elevation Oncology by 302.4% in the 3rd quarter. Barclays PLC now owns 72,077 shares of the company’s stock valued at $43,000 after acquiring an additional 54,167 shares during the period. Institutional investors and hedge funds own 83.70% of the company’s stock.
About Elevation Oncology
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Further Reading
- Five stocks we like better than Elevation Oncology
- The Risks of Owning Bonds
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- How to invest in marijuana stocks in 7 stepsÂ
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.